Jinfiniti's monoclonal antibodies are produced in hybridoma cell lines derived from the fusion of antibody-producing B-lymphocytes and myeloma cells. Jinfiniti’s state-of-the-art technologies ensure rapid high throughput screening and selection of monoclonal antibody clones with high affinity and high titer as well as competitive pricing. We provide up to ten positive clones and guarantee three positive clones for monoclonal antibodies development if antigens meet our standard.